Roche submits NDA for Invirase.
D002986:Clinical Trials as Topic; D017277:Drug Approval; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017387:Investigational New Drug Application; D007546:Isoquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D019258:Saquinavir; D014486:United States Food and Drug Administration; D016047:Zalcitabine / Q000008:administration & dosage / Q000627:therapeutic use; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use
D017320:HIV Protease Inhibitors; D007546:Isoquinolines; D011804:Quinolines; D015215:Zidovudine; D016047:Zalcitabine; D019258:Saquinavir